Moderna, Inc.
MRNAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeModerna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. With a market capitalization of $24.53B, it sits in large-cap territory. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Market Cap
$24.53B
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-15.03
EPS (TTM)
$-7.97
EPS (Fwd)
$-4.11
ROE
-36.6%
ROA
-13.1%
Cash
$5.21B
Total Debt
$1.30B
Free CF
-$20.0M
52W Change
97.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $5.21B in cash comfortably exceeding the $1.30B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$20.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -36.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $18.88B (2022) to $1.92B (2025), a 90% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MRNA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.